Left atrial appendage closure: essential pre-procedural criteria
More than 90% of thrombi in non-valvular atrial fibrillation form in the left atrial appendage (LAA). That makes the appendage a target for stroke prevention, but it does not make every patient a candidate for left atrial appendage closure.
Screening has to establish two things: the patient’s stroke risk justifies an intervention, and the anatomy can be treated without an active thrombus or an unacceptable procedural risk.
The left atrial appendage closure patient screening criteria start with clinical risk scores, then move to imaging and device-specific measurements. Each step answers a different question. A favorable score cannot clear an appendage with thrombus. Suitable anatomy cannot, by itself, justify an implant.
Clinical risk stratification: stroke risk and bleeding risk
Percutaneous LAA closure is considered for selected patients with non-valvular atrial fibrillation who have elevated thromboembolic risk and difficulty taking long-term oral anticoagulation because of contraindication or high bleeding risk. It is a mechanical stroke-prevention strategy. It does not treat atrial fibrillation or remove the need to assess other sources of stroke.
Two scores commonly structure the initial discussion:
| Measure | Screening signal | What it contributes |
|---|---|---|
| CHA₂DS₂-VASc | ≥2 | Indicates elevated thromboembolic stroke risk |
| HAS-BLED | ≥3 | Signals high bleeding risk and prompts closer assessment of anticoagulation safety |
These thresholds help identify patients for evaluation; they are not a stand-alone order to implant. A history of major bleeding may also matter, especially when the clinical team is deciding whether long-term anticoagulation is sustainable. The decision should connect the patient’s stroke risk to the specific reason anticoagulation is unsuitable.
That distinction matters. A high HAS-BLED score flags risk; it does not automatically mean anticoagulants must be stopped or that closure is the correct alternative. The underlying bleeding factors, prior events, current treatment, and the patient’s ability to tolerate the short-term antithrombotic plan after implantation all need review.
Clinical assessment before left atrial appendage closure should therefore establish:
- Whether atrial fibrillation is non-valvular. The evidence summarized here does not support extending these criteria to rheumatic mitral valve disease or mechanical prosthetic heart valves.
- Whether stroke risk is elevated, commonly reflected by CHA₂DS₂-VASc ≥2.
- Whether long-term oral anticoagulation presents a meaningful problem, such as high bleeding risk, HAS-BLED ≥3, or a history of major bleeding.
- Whether the patient can follow the procedure-specific medication and imaging plan after implantation.
The final item is easy to overlook. Closure changes the prevention strategy, but it does not mean antithrombotic therapy can be skipped immediately after the procedure. The post-implant regimen must be considered before scheduling, not improvised after device deployment.
Risk scores open the screening pathway. Imaging and treatment feasibility determine whether it can proceed.
Imaging: exclude thrombus and map the appendage
Pre-procedural imaging for a WATCHMAN device or another LAA closure system has two core jobs: detect thrombus and define appendage anatomy for device selection. Transesophageal echocardiography (TEE, also called TOE) or cardiac CT is used to assess the appendage before the procedure.
An active LAA thrombus is generally a strict contraindication to transcatheter closure. A device should not be advanced into an appendage with an existing clot. Imaging is the gate that identifies this stop condition before the patient enters the deployment phase.
The same study must provide usable measurements. The LAA is not a uniform cavity. Its opening, depth, shape, and orientation affect whether a device can be seated and sealed. The imaging team and implanting operator use those measurements to select a device size and plan the approach. If the anatomy is poorly visualized or the measurements are uncertain, the next step is to resolve that uncertainty, often with the other imaging modality, rather than force a sizing decision from incomplete data.
TEE and cardiac CT offer different imaging routes. The choice depends on the clinical question, image quality, patient factors, and the center’s protocol. The available screening facts establish both modalities as options for thrombus exclusion and anatomical measurement; they do not define a universal rule that one must be used in every patient or that one replaces the other in all cases.
What the imaging review needs to answer
Before the team commits to implantation, the pre-procedural record should make the following points clear:
1. Is there an active appendage thrombus? If present, transcatheter LAA closure should not proceed under the usual screening framework.
2. Can the appendage be measured adequately? The images must support device sizing and a deployment plan.
3. Does the measured anatomy fit the intended device and technique? Suitability depends on the specific system and operator assessment; a favorable clinical profile cannot compensate for anatomy that does not permit reliable seating or sealing.
4. Is the image set sufficient for procedural planning? An unclear study is a planning problem, not a reason to assume the anatomy is suitable.
These are the practical transesophageal echocardiography requirements for LAA closure at the screening stage: rule out thrombus, obtain dimensions, and produce images that can guide device choice. Cardiac CT can serve the same broad pre-procedural purposes when selected by the team.
Contraindications and eligibility boundaries
Patient eligibility for percutaneous LAA occlusion is a convergence of clinical need, anatomy, and procedural feasibility. The procedure is aimed at selected patients with non-valvular atrial fibrillation, elevated stroke risk, and a reason long-term oral anticoagulation is unsuitable or carries substantial bleeding concern.
An active appendage thrombus is the clearest imaging-based stop condition. It is generally considered a strict contraindication to transcatheter closure. The team must also avoid treating the risk scores as a substitute for diagnosis: CHA₂DS₂-VASc and HAS-BLED describe different dimensions of risk. Neither score confirms that a clot is present, defines the appendage anatomy, or guarantees that a patient can complete the post-procedural regimen.
Valvular status also sets a boundary. These criteria should not be transferred to patients with rheumatic mitral valve disease or mechanical prosthetic heart valves. Those groups are outside the non-valvular AF population addressed by this screening pathway.
A useful way to keep the decision sequence disciplined is to separate the questions:
- Clinical indication: Is stroke risk elevated, and is long-term anticoagulation problematic?
- Anatomical eligibility: Is the appendage free of thrombus and measurable for a suitable device?
- Treatment feasibility: Can the patient undergo the procedure and follow the required early medication and surveillance plan?
A failure at any stage changes the route. It may mean reassessing anticoagulation, obtaining better imaging, or determining that closure is not an appropriate option. It does not justify skipping the failed step.
Deployment benchmarks: what PASS checks
Screening ends with a plan; deployment has its own mechanical checks. For a WATCHMAN device, the PASS criteria are assessed before the implant is released. The acronym describes four separate features:
| PASS element | Deployment check | Benchmark |
|---|---|---|
| Position | Assess how far the device protrudes into the left atrium | Less than 50% protrusion |
| Anchoring | Perform the tug test to assess stability | Device remains securely anchored |
| Sealing | Assess residual flow around the device | No residual leak greater than 5 mm |
| Compression | Check device compression after deployment | Approximately 20% |
The checks are related, but they are not interchangeable. A device can appear well positioned and still fail the anchoring test. A stable implant can still have an unacceptable residual leak. Compression is assessed as a separate mechanical parameter.
The operator evaluates all four before release. If a criterion is not met, the device should not be released on the assumption that another favorable measurement offsets the problem. The measurements are part of a deployment decision, not post-hoc documentation.
These thresholds are specific to the described WATCHMAN deployment framework. They should not be treated as universal specifications for every LAA occlusion device. Device instructions and the center’s procedural protocol govern the system actually being implanted.
Post-procedural antithrombotic management remains part of screening
The closure device does not make early medication planning optional. Patients still require an acute post-procedure antithrombotic regimen and clinical follow-up. That point belongs in the eligibility discussion because a patient who cannot tolerate long-term anticoagulation may still need to manage a defined period of therapy after implantation.
There is no universal consensus in the available evidence on antithrombotic duration for patients unable to tolerate short-term direct oral anticoagulants. The plan must therefore be individualized within the treating team’s protocol and the device-specific requirements. It should be agreed before the procedure, with the bleeding history and the patient’s medication constraints explicitly considered.
Follow-up also remains necessary. The implant must be assessed after placement, and the team needs a plan to identify clinically relevant issues such as residual leak or device-related complications. Closure is a change in the stroke-prevention approach, not an endpoint that eliminates surveillance.
For clinicians mapping the decision, the route is direct: confirm non-valvular AF and elevated stroke risk; establish why long-term anticoagulation is unsuitable; image the appendage to exclude thrombus and measure anatomy; agree on the short-term antithrombotic and follow-up plan; then apply device-specific deployment checks. Any unresolved thrombus, sizing, or medication question is a reason to pause.
The bottom line is binary. If clinical risk, thrombus-free imaging, suitable anatomy, and a workable post-procedure plan align, proceed to device-specific planning. If one of those gates fails, do not deploy.